Reasons to Keep Cardinal Health Inc. Stock in Your Investment Strategy
Cardinal Health Inc. (NYSE: CAH) is strategically positioned for significant growth, with a focus on acquisitions and a diverse array of products, particularly in its robust pharmaceutical segment. Despite facing inflationary pressures, the outlook for CAH appears encouraging.
Year-to-date, shares of Cardinal Health have impressively climbed by 11.1%, contrasting sharply with the industry’s decline of 1.7%. If you compare this with the S&P 500 Index, which saw a 20.6% rise in the same timeframe, it reflects strong relative performance.
With a market capitalization of $27.09 billion, Cardinal Health is a leading distributor and service provider for the pharmaceutical and healthcare sectors. Its earnings yield stands at 6.8%, further enhancing its attractiveness to investors compared to the industry's average of 5.3%. The company anticipates a promising earnings growth rate of 9.6% over the coming five years.
Key Factors Boosting Cardinal Health's Performance
Strength in the Pharmaceutical Sector: Investors remain optimistic about Cardinal Health's pharmaceutical offerings, which provide a competitive edge in the market. The company's pharmaceutical division encompasses a range of services, including distribution, specialty solutions, and nuclear pharmacy services, all of which are expected to drive revenue growth in the coming quarters.
In the fourth quarter of the fiscal year, pharmaceutical revenues reached $55.6 billion, reflecting a year-over-year increase of 13%. This growth is largely attributed to the rise in branded pharmaceutical sales.
Looking ahead, Cardinal Health predicts a year-over-year revenue decline of 4-6% in its pharmaceutical sector due to the expiration of a significant contract with OptumRx that contributed $39 billion in revenues. However, segment profits are expected to grow by 1-3%, signaling resilience despite challenges.
Long-term Partnerships: The company is strengthening its market position through strategic joint ventures and supply agreements. A notable collaboration with Henry Schein involves the procurement of medical supplies, aimed at enhancing core sales and boosting earnings.
Additionally, a substantial 15-year agreement with Bayer Healthcare for contract manufacturing of Xofigo aims to leverage Cardinal Health’s expertise in the nuclear pharmacy industry, enhancing access to essential radiopharmaceutical treatments.
Strong Quarterly Results Fuel Investor Confidence
Cardinal Health reported solid fourth-quarter results for fiscal 2024, showcasing impressive top-line growth driven by its pharmaceutical segment. Management noted robust sales growth from established customer relationships, leading to a 5% year-over-year increase in gross profit.
Recent Strategic Developments
Recently, Cardinal Health announced plans to acquire Integrated Oncology Network for $1.115 billion in cash. This acquisition is expected to significantly enhance CAH's oncology strategy and empower community practices with advanced technologies and analytics.
In another development, Cardinal Health signed a distribution agreement with Telix Pharmaceuticals to provide radiopharmaceuticals for kidney cancer imaging in the U.S., pending regulatory approval. This partnership expands CAH's footprint in the radiopharmaceutical market.
Furthermore, a new distribution center in Greenville, South Carolina, dedicated to at-home healthcare solutions, is on track to create around 200 jobs, thereby supporting the growing demand for at-home healthcare services.
Challenges Facing the Stock
Despite the growth potential, Cardinal Health is not without risks. The company faces significant revenue challenges if it loses any major customers, particularly given that over 20% of its business currently depends on CVS Caremark post their 2014 joint venture.
Five key customers, including CVS, make up approximately 40% of revenue, underlining the vulnerability of CAH's revenue streams. Notably, the OptumRx contracts that contributed 17% of CAH's revenues in fiscal 2023 have concluded, posing potential sales declines in the upcoming fiscal year.
Additionally, Cardinal Health faced scrutiny from the FDA regarding quality control issues related to its Presource kit plastic syringes, resulting in product recalls. Such regulatory challenges highlight the importance of maintaining high standards for patient safety.
Projected Financial Estimates
Current estimates suggest a projected revenue for fiscal 2025 at $215.84 billion, reflecting a decline of 4.9% from the previous fiscal year. However, adjusted earnings per share estimates have improved slightly to $7.61, indicating a modest increase of 1.1% from last year, showcasing some resilience.
Investment Opportunities in Healthcare Sector
Investors might also want to consider alternative stocks within the healthcare sector that are currently performing well. Stocks like Universal Health Service (NYSE: UHS), Quest Diagnostics (NYSE: DGX), and Baxter International (NYSE: BAX) carry favorable Zacks Rank #2 (Buy) ratings, indicating strong buy potential.
Universal Health Service boasts a robust estimated long-term growth rate of 19%, while Quest Diagnostics has a growth rate of 6.2%, both surpassing industry averages in recent earnings reports. Baxter International has consistently delivered earnings outperforming expectations despite recent share price weakness.
Frequently Asked Questions
1. What are the main strengths of Cardinal Health?
Cardinal Health's strengths include a strong pharmaceutical segment, diverse product offerings, and strategic partnerships that position it for future growth.
2. How has Cardinal Health performed this year?
The stock has risen by 11.1%, significantly outperforming the industry average of a 1.7% decline.
3. What challenges does Cardinal Health face?
The company faces risks related to dependency on key customers and potential declines in revenue from contract expirations.
4. How are Cardinal Health's earnings forecasts for the coming years?
Analysts predict a 4.9% decline in revenue for fiscal 2025 but a slight increase in adjusted earnings per share.
5. Which stocks are comparable to Cardinal Health in the market?
Stocks like Universal Health Service, Quest Diagnostics, and Baxter International present strong investment opportunities in the healthcare sector.
